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Spinal muscular atrophy: Clinical 
spectrum and genetic mutations in 
Pakistani children
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Abstract 
Background: In Pakistan the rate of consanguineous marriages is high, thus, the chance 
of incidence of autosomal recessive disorders is likely to be high. The aim of this study is 
to investigate the clinical characteristics and genetics of spinal muscular atrophy (SMA) 
in children who presented to Aga Khan University, Karachi. Materials and Methods: This 
study was a retrospective review of the medical charts of children (neonate: 15 years) with 
discharge diagnosis of SMA during last 10 years. Demographic features, consanguinity, 
and diagnostic analysis (including genetic analysis) were noted. Results: During the study 
period 67 children had a discharge diagnosis of SMA. Werdnig Hoffman disease (SMA 
type  I) was the commonest variant seen in 37 (56%) children. Overall 68% were infants. 
High parental consanguinity was observed in 68% of the study cohort. The history of 
delayed development and undiagnosed early death was observed in the families of 19 
children. Genetic testing was performed in 22 (33%) children. Survival motor neuron (SMN) 
1 gene deletion was found in 19 (86%) of the 22 patients in whom the gene analysis 
was done and 13 (68%) were also positive for neuronal apoptosis inhibitory proteins 
(NAIP) deletion. Conclusion: SMA is not an uncommon neurodegenerative disorder 
in Pakistan and SMA type I was the most common type. SMN1 gene deletion was 
the most common genetic deletion found in this study. In addition, family history of 
developmental delay and frequent early deaths highlights the need for implementation 
of prenatal diagnosis for early detection, effective control, and management of this 
disorder in Pakistan.
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of alpha motor neurons, leading to muscle atrophy, 
paralysis, and even death.[1] Mostly it has a recessive 
inheritance; however, autosomal dominant and X-linked 
inheritance has been documented.[2] The reported 
incidence is about 1 in 10,000 live births with a carrier 
frequency of 1 in 50.[3] The gene for SMA, survival motor 
neuron (SMN1) has been mapped on the 5q11.2–13.3 
region and there are two copies of SMN gene: SMN1 and 
SMN2.[4] Most common mutation found in SMA patients 
is homozygous deletion of SMN1 exon 7; however, 
many compound heterozygous subjects with different 
deletions and point mutation have been documented.[5] 
All patients with SMA lack a functioning SMN1 gene 
Introduction
Spinal muscular atrophy (SMA) is a neurodegenerative 
disease characterized by progressive degeneration 
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muscle weakness and atrophy, tremor of fingers and 
hands, tongue fasciculation along with absent or greatly 
decreased deep tendon reflexes[4] and electromyographic 
(EMG) evidence of denervation, preganlionic anterior 
horn cells.[3] Molecular genetic testing was aimed 
at detecting bi-allelic deletions or mutations in the 
survival motor neuron 1 (SMN1) gene on chromosome 
5q13 (exon  7 and exon 8) and/or neuronal apoptosis 
inhibitory protein (NAIP) gene. Muscle biopsy was not 
done in any of the patients.
Gene analysis 
Genomic deoxyribonucleic acid (DNA) was isolated 
from blood samples using column based DNA extraction 
kit obtained from Promega (USA). Deletion of exon  7 
and 8 of SMN 1 gene was examined by polymerase 
chain reaction (PCR) amplification and restriction 
endonuclease digestion according to the method of 
Steege et al.[15] PCR amplification was carried out for 
35 cycles in PCR mixture containing 100 ng DNA, 75 ng 
of each primer, 200 μM of dNTPs, 1.5 MgCl2, 2.5U Taq 
polymerase in a final volume of 50 μL. PCR products of 
exon 7 were digested with Dra I, and exon 8 with DdeI. 
The digestion pattern of the PCR product was evaluated 
according to the protocol described by Steege et al.[15] 
The deletion of exon 5 of NAIP was identified by using 
the method described by Roy et al.[16] Along with exon 5; 
exon 13 of NAIP was also amplified and used a control 
to monitor the performance of PCR assay. 
Statistical analysis
The retrieved data were analyzed on SPSS version 19. 
Demographic features included age in days, weight, 
gender, presenting complaint at admission or health 
seeking, year of admission, consanguinity, perinatal 
depression, developmental delay or any other 
early death/s within the family were retrieved. 
Electromyography and nerve conduction study (EMG/
NCV) and genetic analysis data were also retrieved and 
reported. SMN and NAIP gene mutations were reported 
among positive patients. Because of descriptive nature of 
the data only frequency and percentages were calculated.
Results
After chart review during the study period 67 children 
who fulfilled the inclusion criteria. Of the 67 patients 
42 (63%) were infants and 7 were neonates. There was 
male predominance, 38 (57%) and male to female ratio 
was  1.2:1. Children were further divided according to 
the SMA types 1 to 3 [Table 1]. Developmental delay 
was the main presenting feature (45%) followed by, 
generalized weakness, hypotonia and respiratory 
difficulty. SMA type I accounted for 56% (n=37) of 
the cohort. Mean age at presentation in SMA-type 
1 was 3.3±1.7 months (median; 3 months). Overall 
and are thus dependent on their SMN2 gene for SMN 
protein, which is nonfunctional and rapidly degraded, 
leading to selective degeneration of spinal and cranial 
motor neurons.[6] 
Phenotypically SMA has extreme variability and 
clinically classified:[7] SMA type I (severe variant, 
Werdnig–Hoffman) with age of onset before 6 months, 
may not sit, and usually die before their second 
birthday; SMA type  II (intermediate variant) with age 
of onset between 7–18 months, may sit but never stand 
and death usually after 2 years of age; SMA type III 
(mild variant, Kugelberg–Welander) with age of onset 
~18 months of age and death is in adult life; and SMA 
type IV (adult varients) presents in the second or third 
decade, individuals walk during the adulthood and 
death occurs in adult life.[3] There other form is SMA 
type 0 or embryonic form (lethal variant), characterized 
by reduced fetal movements between 30–36 weeks 
of pregnancy with a very short life expectancy.[8] The 
clinical characteristics of the disorder are: hypotonia, 
symmetrical proximal weakness, atrophy, and reduced 
to absent deep tendon reflexes.[4] Genetic diagnosis by 
using polymerase chain reaction (PCR)-based DNA 
methods have been developed to detect deletions in both 
SMN and Neuronal apoptosis inhibitory (NAIP) gene.[2,9] 
SMA is an autosomal recessive and consanguineous 
marriage increases the risk of the disease in the family. 
High prevalence of SMA has been reported in Iran, Egypt, 
and Saudi Arabia where consanguineous marriage 
rates are high.[10-13] Pakistan has one of the highest 
reported consanguineous marriage rate in the world, 
approximately 61% marriages.[14] With this high-rate 
consanguineous marriage, we expect a high burden of 
SMA in Pakistan. This report describes the demographic 
features, clinical characteristics, and genetic diagnosis of 
children with SMA in the Pakistani population.
Materials and Methods
Identification of study population 
This was a retrospective chart review of children 
(neonate, 15 years) seen in the last 10 years (January 
2001 to December 2010) and children with a diagnosis of 
SMA were evaluated. The sources of subjects included 
in this study were (i) inpatients discharge records with a 
diagnosis of SMA, ICD code (International Classification 
of Disease, 2008 (ICD9) 335.1 and 335.1 and (ii) data from 
the electrodiagnostic laboratory and genetic laboratory 
(SMA gene analysis). This study was approved by 
the Institutional ethical review committee; Aga Khan 
University, Karachi.
Case definition
Diagnosis of SMA was considered in any child with 
generalized hypotonia, diffuse symmetrical proximal 
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Discussion
Werdnig–Hoffman disease (SMA-1) is the most severe 
clinical type of SMA and prenatal onset of SMA has also 
been defined.[10,17] It is associated with high morbidity 
and mortality. In our study majority of patients (61%) 
were infants at the time of presentation similar to the 
observations in other studies.[10,17,18] Males had a slightly 
higher preponderance than females in our study 
and this also has been reported in the literature.[10,17] 
Consanguinity was very high in our study. The reported 
consanguinity in the earlier studies ranged between 
38.9% and 49%.[10,17,19] High consanguinity would reflect 
the autosomal recessive inheritance of this disease. 
Table  2 compares the consanguinity rates among SMA 
children from different countries. Early or previous 
deaths in family and history of developmental delay 
may be the additional features indicating a genetic 
background of this disease in our study cohort. 
More than 98% of patients with spinal muscular atrophy 
have a homozygous disruption of SMN1 by deletion, 
rearrangement, or mutation.[3] The clinical severity is 
influenced by the number of copies of SMN2 gene. It 
has been observed that 95% of SMA type I patients have 
only 1-2 copies of SMN2, whereas almost all patients 
belonging to type III had 3 or more copies.[20] Because 
of this, the children belonging to these groups have less 
severe form of disease.[21] The most common deletion 
found in our cohort was of SMN1. Exon 7 and 8 in 
SMN1gene was deleted in majority of positive children. 
Similar was the observation in the Egyptian cohort, in 
this study the frequency of homozygous deletion of exon 
7 and 8 were present in 54.5–80% of patients irrespective 
of their clinical severity.[22] In our cohort NAIP was the 
most common deletion (68%) among children tested for 
genetic testing; 10 (77%) of them were SMA type  1. The 
frequency of NAIP deletion was also found to be more 
frequent in SMA type I (80%) as compared to type  II 
(22%) and type III (50%) in the Egyptian cohort.[22] 
However, the incidence was much higher (100%) in the 
studies from Kuwait and Saudi Arabia.[10,13] Interestingly 
all the three children with SMA II in our study had gene 
deletion for both NAIP and SMN1 gene. The reported 
frequency of NAIP deletion is relatively lower for both 
SMA II and  III.[17,23] Very few children with SMA II 
and SMA III had genetic testing and therefore we are 
unable to draw any significant conclusion from these 
results. Larger samples are needed to further explain 
the genetic basis of SMA type II and III patients in 
our population. Genetic testing was negative in three 
children. The 5q-SMA genetic testing is 95% sensitive 
and 100% specific.[23] Fiver percent (1/20) of affected 
individuals with 5q-SMA have rare point mutation that 
are not detected by the SMN genetic testing. Most of 
these children have one SMN1 gene with SMN1 exon 7 
18 (31%) children were severely malnourished (weight 
for age;  <5th percentile). The history of parental 
consanguinity was present in 53 (73%) children 
and them 36 (68%) had consanguineous marriages 
[Figure  1]. Perinatal depression was positive among 
20 (34%) on the 58 children where such history was 
documented; while family history of developmental 
delay and/or spinal muscular atrophy was found 
in 19 (45%) of 42 children where such history was 
documented. The history of early deaths in the family 
was present in 19 (37%) of the 52 children with the 
data available. EMG/nerve conduction studies were 
performed in 62 patients, showing positive sharp 
waves, fibrillation, and/or fasciculation in all, and were 
consistent with the diagnosis of SMA. 
Gene analysis was done in 22 children; among them 19 
were positive (86%), genetic testing results were negative 
in 3 (13%) children. All positive patients showed a 
deletion of exon 7 and 8 in SMN1 gene. Exon 5 deletion 
of NAIP gene was also found positive in 13 (68%) of the 
19 patients [Table 1]. Out of 20 hospitalized patients 
5 (25%) children died. All died because of respiratory 
failure and were diagnosed as SMA type 1. The mean 
age at death was 3.9±1.2 months.
Table 1: Baseline features and genetic identification of children 
with spinal muscular atrophy
Variables^ SMA type 1*   
(n = 37)
SMA type 2* 
(n = 15)
SMA type 
3*(n = 15)
Mean age of 
presentation (± SD)
3.3 ± 1.7 mo 15 ± 4 mo 70 ± 2 mo
Male 23 (62%) 6 (40%) 9 (60%)
Main presenting 
complaint
Respiratory difficulty
Developmental delay
Failure to thrive
Weakness / Hypotonia
Walking difficulty
Fever/ Lethargy/  
Sepsis/ Poor intake
10
14
--
7
--
6
1
7
1
4
--
1
--
9
--
5
1
--
Weight <5th centile 10 (33%) 3 (40%) 5 (36%)
Consanguinity in  
parents
21 (66%) 9 (82%) 6 (60%)
Perinatal depression 12 (35%) 6 (54%) 2 (15%)
Positive family history
Diagnosed SMA/ 
Developmental delay
Early deaths
12 (55%)
14 (47%)
4 (50%)
3 (27%)
3 (40%)
2 (18%)
Genetic analysis of SMA 
patients
Exon 7 and 8 deleted in 
SMN 1 gene
2 -- 4
Both NAIP and SMN 1 
gene deleted
10 3 --
Negative 1 1 1
*Adapted from reference(6) ^ Because of missing values the data, the denominator 
was changed for each subcategory. Spinal muscular atrophy (SMA); survival 
motor neuron (SMN); neuronal apoptosis inhibitory (NAIP).
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missing and a second SMN1 gene with a rare point 
mutation.[23]
Currently there is no available cure for SMA; one possible 
intervention could be to reduce the consanguinity by 
educating the population. This will eventually interrupt 
the transmission by reducing carrier state. With the 
availability of genetic testing it is now possible to 
diagnose these children early so that appropriate 
counseling can be given to the family on the risk of 
future pregnancies. Early identification by genetic 
testing has also opened the way for early antenatal 
diagnosis. 
Limitations
Genetic testing for SMA in our university was started 
from 2005; hence, data on genetic testing were only 
present for patients after this period. Some families 
denied genetic testing due to various reasons. With 
these limitations this is the first study from Pakistan 
that reports clinical spectrum and genetic testing of 
SMA patients.
Conclusion
SMA-1 is the commonest SMA type in our study 
population. Deletion of exon 7 and exon 8 in SMN1 gene 
is the commonest deletion in our SMA study cohort; 
however, an exon 5 deletion in NAIP gene is also very 
high. This study highlights the need for implementation 
of prenatal diagnosis in high risk consanguineous 
populations like Pakistan to reduce the burden of the 
disease.
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